nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-169-9-17-26nogr-1188Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYГастроэнтеропротекция при лечении эрозивно-язвенных поражений желудка и тонкой кишкиGastroprotection in the treatment of erosive and ulcerative lesions of the stomach and small intestineПлотниковаЕ. Ю.PlotnikovaE. Yu.

Плотникова Екатерина Юрьевна, д. м. н., профессор кафедры подготовки врачей первичного звена здравоохранения, руководитель курса клинической гастроэнтерологии, 650056, г. Кемерово, ул. Ворошилова, 22А

Ekaterina Yu. Plotnikova, MD, Professor of the Department of training of primary care physicians, head of the course ofclinical gastroenterology, 650056, Kemerovo, Voroshilov street, 22A

eka-pl@rambler.ruВологжанинаЛ. Г.VologdaninaL. G.

Вологжанина Людмила Георгиевна, к. м. н., доцент кафедры факультетской терапии № 1, 614990, Пермский край, г. Пермь, ул. Петропавловская, д. 26

Lyudmila G. Vologdanina, Ph. D., associate Professor of the Department of faculty therapy № 1, 614990, Perm region, Perm, 26 Petropavlovsk street

КороткевичА. Г.KorotkevichA. G.

Короткевич Алексей Григорьевич, д. м. н., профессор, заведующий отделением эндоскопии, 654005, Кемеровская область, г. Новокузнецк, проспект Строителей, д. 5

Alexey G. Korotkevich, MD, Professor, head of the Department of endoscopy, 654005, Kemerovo region, Novokuznetsk, Avenue of Builders, d. 5

ГрачеваТ. Ю.GrachevaT. Yu.

Грачева Татьяна Юрьевна, д. м. н., зав. кафедрой судебной медицины и медицинского права, 650056, г. Кемерово, ул. Ворошилова, 22А

Tatiana Yu. Gracheva, Ph. D., head. Department of forensic medicine and medical law, 650056, Kemerovo, Voroshilov street, 22A

Федеральное Государственное Бюджетное Учреждение Высшего Образования Кемеровский государственный медицинский университет Минздрава РоссииРоссияFederal State Budgetary Institution of Higher Education Kemerovo state medical University of the Ministry of health of RussiaRussian FederationФедеральное Государственное Бюджетное Учреждение Высшего Образования Пермский государственный медицинский университет им. академика Е. А. Вагнера Минздрава РоссииРоссияFederal State Budgetary Institution of Higher Education Perm state medical University. academician E. A. Wagner, Ministry of health of RussiaRussian FederationНовокузнецкий государственный институт усовершенствования врачей — филиал ФГБОУ ДПО РМАНПО Минздрава РоссииРоссияState doctors improvement Institute of Novokuznetsk — a branch of FGBOU DPO RMAPO Ministry of health of RussiaRussian Federation201920092019091726Copyright © Плотникова Е.Ю., Вологжанина Л.Г., Короткевич А.Г., Грачева Т.Ю., 20202020Плотникова Е.Ю., Вологжанина Л.Г., Короткевич А.Г., Грачева Т.Ю.Plotnikova E.Y., Vologdanina L.G., Korotkevich A.G., Gracheva T.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/1188

 В статье описываются причины эрозивно-язвенных повреждений желудка, тонкой кишки. Особое внимание уделяется приему нестероидных противовоспалительных препаратов, нарушению микроциркуляции. Подробно рассмотрены побочные эффекты нестероидных противовоспалительных препаратов и ингибиторов протонной помпы. Выделены группы пациентов с эрозивно-язвенными повреждениями желудка, тонкой кишки с диспепсией, которым не показано назначение ингибиторов протонной помпы. Ребамипид может назначаться для профилактики и лечения эрозивно-язвенных повреждений желудка, тонкой кишки с диспепсией, как с ингибиторами протонной помпы, так и в виде монотерапии с целью гастропротекции пациентам, у которых применение ингибиторов протонной помпы нецелесообразно. Предложен алгоритм гастропротекции в зависимости от состояния желудочной кислотосекреции пациентов.

In article the reasons of erosive and ulcer injuries of a stomach, a small intestine are described. Special attention is paid to intake of nonsteroid anti-inflammatory medicines, microcirculation violation. Side effects of nonsteroid anti-inflammatory medicines and inhibitors of a proton pomp are in detail considered. Groups of patients with erosive and ulcer injuries of a stomach, small intestine with dyspepsia to which purpose of inhibitors of a proton pomp is not shown are allocated. Rebamipide can be appointed for prevention and treatment of erosive and ulcer injuries of a stomach, a small intestine with dyspepsia, both with inhibitors of a proton pomp, and in the form of monotherapy for the purpose of a gastroprotection to patients when use of inhibitors of a proton pomp is inexpedient. The gastroprotection algorithm depending on a condition of a gastric acid secretion of patients is offered.

эрозивно-язвенные повреждения желудкатонкой кишкидиспепсиянестероидные противовоспалительные препаратыингибиторы протонной помпыребамипидerosive and ulcer injuries of a stomachsmall intestineorganic dyspepsianonsteroid anti-inflammatory medicinesinhibitors of a proton pomprebamipideReferencesСоловьева, Г. А. Эрозии желудка – отдельная нозологическая форма или универсальная реакция слизистой оболочки на повреждение? Внутренняя медицина. 2007; 3: 96–99.Solovyova, G. A. Erosion of a stomach there is a separate nosological form or universal reaction of a mucous membrane to damage? Internal medicine. 2007; 3: 96–99.Жураховская Д.В., Лоскутова Е. Е., Виноградова И. А. Маркетинговый анализ фармацевтического рынка нестероидных противовоспалительных препаратов на региональном уровне. Современные проблемы науки и образования. 2014; 2. URL: http://science-education.ru/ru/article/view?id=12853Zhurakhovskaya D. V., Loskutova E. E., Vinogradova I. A. The marketing analysis of the pharmaceutical market of nonsteroid anti-inflammatory medicines at the regional level. Modern problem sof science and education. 2014; 2. URL: http://science-education.ru/ru/article/view?id=12853Насонов Е. Л., Цветкова Е. С., Балабанова Р. М. и др. Новые аспекты противовоспалительной терапии ревматических заболеваний: теоретические предпосылки и клиническое применение мелоксикама. Клиническая медицина. 1996; 4: 4–8.Nasonov E. L., Tsvetkova E. S., Balabanova R. M., etc. New aspects of anti-inflammatory therapy of rheumatic diseases: theoretical prerequisites and clinical application of a meloksikam. Wedge. medicine. 1996; 4: 4–8.Каратеев А.Е., Насонов Е. Л., Яхно Н. Н., Ивашкин В. Т., Чичасова Н. В., Алексеева Л. И., Карпов Ю. А., Евсеев М. А., Кукушкин М. Л., Данилов А. Б., Воробьева О. В., Амелин А. В., Новикова Д. С., Драпкина О. М., Копенкин С. С., Абузарова Г. Р. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4–23. https://doi.org/10.14412/1996–7012–2015–1–4–23.Karateev A. E., Nasonov E. L., Yakhno N. N., et al. Clinical recommendations «Rational use of nonsteroidanti-inflammatory medicines (NSAIDs) in clinical practice». Modern rheumatology. 2015;9(1): 4–23. https://doi.org/10.14412/1996–7012–2015–1–4–23.Щекина Е.Г., Дроговоз С. М., Страшный В. В. НПВС – проблемы безопасности. Провизор. 2003; 4: 8–11.Shchyokino E. G., Drogovoz S. M., Terrible V. V. NPVS – security concerns. Pharmacist. 2003; 4: 8–11.Каратеев А. Е. Нимесулид: мифы и реальность. Справочник поликлинического врача. 2013; 4: 56–61.Karateev A. E. Nimesulid: myths and reality. Reference book by the polyclinic doctor. 2013; 4: 56–61.Шавловская О. А. Амтолметингуацил: опыт применения в клинической практике. Справочник поликлинического врача. 2014; 7: 54–58.Shavlovsky O. A. Amtolmetinguatsit: experience of application in clinical practice. Reference book by the polyclinic doctor. 2014; 7: 54–58.Tavella A., Ursini G. Studio clinico sull’attivita antiinflamatoria e sulla tollerabilita gastro-enterica di amtolmetineguacil, un nuovo FANS, in confronto a diclofenac su pazienti anziani con patologie osteoarticolari. Clin. Ter. 1997; 148: 543–548.Tavella A., Ursini G. Studio clinico sull’attivita antiinflamatoria e sulla tollerabilita gastro-enterica di amtolmetineguacil, un nuovo FANS, in confronto a diclofenac su pazienti anziani con patologie osteoarticolari. Clin. Ter. 1997; 148: 543–548.Belisari A., Mantovani L. G. Cost-benefi t analysis of amtolmetin-guacil. Clin Drug Invest. 2001;21(1): 47–58.Belisari A., Mantovani L. G. Cost-benefi t analysis of amtolmetin-guacil. Clin Drug Invest. 2001;21(1): 47–58.Наумов А.В., Семенов П. А. Боль в России: факты и умозаключения. Consilium Medicum. 2010; 02: 42–48.Naumov A. V., Semyonov P. A. Pain in Russia: facts and conclusions. Consilium Medicum. 2010; 02: 42–48.Плотникова Е.Ю., Золотухина В. Н., Мерзляков С. П., Вологжанина Л. Г., Синькова М. А. Нестероидные противовоспалительные препараты при вертеброгенных болевых синдромах – что выбрать? Сравнительное исследование. Нервные болезни. 2018; 2: 38–42.Plotnikova E. Yu., Zolotukhina V. N., Merzlyakov S. P., Resident of Vologda L. G., Sinkova M. A. Non steroid anti-inflammatory medicines at the vertebrogennykh pain syndromes – what to choose? Comparativere search. Nervous diseases. 2018; 2: 38–42.Чибыева Л.Г., Федотова А. П., Васильев Н. Н., Николаева К. М., Николаева В. М. Гастродуоденальные повреждения, индуцированные приемом нестероидных противовоспалительных препаратов, в условиях республики Саха (Якутия). Вестник СВФУ. 2010; 7(4): 41–46.Chibyeva L. G., Fedotova A. P., Vasilyev N. N., Nikolaeva K. M., Nikolaeva V. M. The gastroduodenal damages induced by intake of nonsteroid anti-inflammatory medicines in the conditions of the Sakha (Yakutia) Republic. SVFU bulletin. 2010; 7(4): 41–46.Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Sys Rev. 2012; 12: 9. CD007400 47.Derry S, Moore R, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Sys Rev. 2012; 12: 9. CD007400 47.Sostres C, Gargallo C, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther, 2013; 15(3): 3.Sostres C, Gargallo C, Lanas A. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther, 2013; 15(3): 3.Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct; 68(10):1219–32. doi: 10.1111/all.12260.Kowalski ML, Asero R, Bavbek S, et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy. 2013 Oct; 68(10):1219–32. doi: 10.1111/all.12260.White A.A., Stevenson D. D. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588–94. doi: 10.1055/s-0032–1325618.White A.A., Stevenson D. D. Aspirin-exacerbated respiratory disease: update on pathogenesis and desensitization. Semin Respir Crit Care Med. 2012 Dec;33(6):588–94. doi: 10.1055/s-0032–1325618.Boghossian T.A., Rashid F. J., Thompson W., Welch V., Moayyedi P., Rojas-Fernandez C., Pottie K., Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Systematic Review – Intervention Version published: 16 March 2017. https://www.cochranelibrary.com/cdsr/ doi/10.1002/14651858.CD011969.pub2/fullBoghossian T.A., Rashid F. J., Thompson W., Welch V., Moayyedi P., Rojas-Fernandez C., Pottie K., Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Systematic Review – Intervention Version published: 16 March 2017. https://www.cochranelibrary.com/cdsr/ doi/10.1002/14651858.CD011969.pub2/fullLinsky A., Gupta K., Lawler E. V., Fonda J. R., Hermos J. A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.Linsky A., Gupta K., Lawler E. V., Fonda J. R., Hermos J. A. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med. 2010;170(9):772–8.Sarkar M., Hennessy S., Yang Y. X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008; 149(6):391–8.Sarkar M., Hennessy S., Yang Y. X. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008; 149(6):391–8.Herzig S.J., Howell M. D., Ngo L. H., Marcantonio E. R. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. Jama. 2009;301(20):2120–8.Herzig S.J., Howell M. D., Ngo L. H., Marcantonio E. R. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. Jama. 2009;301(20):2120–8.Laine L., Ahnen D., McClain C., Solcia E., Walsh J. H. Review article: potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors. Aliment Pharmacol Th er. 2000;14(6):651–68.Laine L., Ahnen D., McClain C., Solcia E., Walsh J. H. Review article: potential gastrointestinal effects of longterm acid suppression with proton pump inhibitors. Aliment Pharmacol Th er. 2000;14(6):651–68.Ali T., Roberts D. N., Tierney W. M. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896–903.Ali T., Roberts D. N., Tierney W. M. Long-term safety concerns with proton pump inhibitors. Am J Med. 2009;122(10):896–903.Vestergaard P., Rejnmark L., Mosekilde L. Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture. Calcif Tissue Int. 2006;79(2):76–83.Vestergaard P., Rejnmark L., Mosekilde L. Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture. Calcif Tissue Int. 2006;79(2):76–83.Yu E., Blackwell T., Ensrud K., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.Yu E., Blackwell T., Ensrud K., et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008;83(4):251–9.Targownik L.E., Lix L. M., Metge C. J., Prior H. J., Leung S., Leslie W. D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.Targownik L.E., Lix L. M., Metge C. J., Prior H. J., Leung S., Leslie W. D. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–26.Corley D.A., Kubo A., Zhao W., Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients. Gastroenterology. 2010;139(1):93–101.Corley D.A., Kubo A., Zhao W., Quesenberry C. Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients. Gastroenterology. 2010;139(1):93–101.FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Rockville, MD: U. S. Food and Drug Administration; [Accessed July 5, 2010]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/u.cm213206.htm.FDA Drug Safety Communication. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. Rockville, MD: U. S. Food and Drug Administration; [Accessed July 5, 2010]. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/u.cm213206.htm.Elaine W. Yu., Scott R., Bauer B. S., Bain P. A., Bauer D. C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011 Jun; 124(6): 519–526. doi: 10.1016/j.amjmed.2011.01.007.Elaine W. Yu., Scott R., Bauer B. S., Bain P. A., Bauer D. C. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011 Jun; 124(6): 519–526. doi: 10.1016/j.amjmed.2011.01.007.Recker R. R. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.Recker R. R. Calcium absorption and achlorhydria. N Engl J Med. 1985;313(2):70–3.Tuukkanen J., Vaananen H. K. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123–5.Tuukkanen J., Vaananen H. K. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986;38(2):123–5.Kocsis I., Arato A., Bodanszky H., et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int. 2002;71(2):129–32.Kocsis I., Arato A., Bodanszky H., et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int. 2002;71(2):129–32.Mizunashi K., Furukawa Y., Katano K., Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.Mizunashi K., Furukawa Y., Katano K., Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993;53(1):21–5.Hansen K.E., Jones A. N., Lindstrom M. J., et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010 Dec; 25(12): 2786–2795.Hansen K.E., Jones A. N., Lindstrom M. J., et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res. 2010 Dec; 25(12): 2786–2795.Kirkpantur A., Altun B., Arici M., Turgan C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clinical Practice. 2009;63(2):261–8.Kirkpantur A., Altun B., Arici M., Turgan C. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients. Int J Clinical Practice. 2009;63(2):261–8.Targownik L.E., Lix L. M., Leung S., Leslie W. D. Proton Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology. 2010 Mar;138(3):896–904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.Targownik L.E., Lix L. M., Leung S., Leslie W. D. Proton Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss. Gastroenterology. 2010 Mar;138(3):896–904. doi: 10.1053/j.gastro.2009.11.014. Epub 2009 Nov 18.Dharmarajan T.S., Kanagala M. R., Murakonda P., Lebelt A. S., Norkus E. P. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008; 9(3): 162–7.Dharmarajan T.S., Kanagala M. R., Murakonda P., Lebelt A. S., Norkus E. P. Do acid-lowering agents affect vitamin B12 status in older adults? J Am Med Dir Assoc. 2008; 9(3): 162–7.Valuck R.J., Ruscin J. M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004; 57(4):422–8.Valuck R.J., Ruscin J. M. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004; 57(4):422–8.McLean R.R., Jacques P. F., Selhub J., et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350(20):2042–9.McLean R.R., Jacques P. F., Selhub J., et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004;350(20):2042–9.Gerdhem P., Ivaska K. K., Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22(1):127–34.Gerdhem P., Ivaska K. K., Isaksson A, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22(1):127–34.Epstein M., McGrath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.Epstein M., McGrath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–6.Faulhaber G.A., Furlanetto T. W. Could magnesium depletion play a role on fracture risk in PPI users? Arch Intern Med. 2010 Oct 25;170(19):1776. doi: 10.1001/archinternmed.2010.374.Faulhaber G.A., Furlanetto T. W. Could magnesium depletion play a role on fracture risk in PPI users? Arch Intern Med. 2010 Oct 25;170(19):1776. doi: 10.1001/archinternmed.2010.374.Brozek W., Reichardt B., Zwerina J., Dimai H. P., Klaushofer K., Zwettlera E. Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study. Bone Rep. 2019 Jun; 10: 100204. doi: 10.1016/j.bonr.2019.100204.Brozek W., Reichardt B., Zwerina J., Dimai H. P., Klaushofer K., Zwettlera E. Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study. Bone Rep. 2019 Jun; 10: 100204. doi: 10.1016/j.bonr.2019.100204.Poly T.N., Islam M. M., Yang H. C., Wu C. C., Li Y. J. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103–114. doi: 10.1007/s00198–018–4788-y.Poly T.N., Islam M. M., Yang H. C., Wu C. C., Li Y. J. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103–114. doi: 10.1007/s00198–018–4788-y.Haenisch B., von Holt K., Wiese B., et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265: 419–428.Haenisch B., von Holt K., Wiese B., et al. Risk of dementia in elderly patients with the use of proton pump inhibitors. Eur Arch Psychiatry Clin Neurosci 2015; 265: 419–428.Arai N., Nakamizo T., Ihara H., et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. P LoS One 2017; 12(1): e0169300.Arai N., Nakamizo T., Ihara H., et al. Histamine H2-blocker and proton pump inhibitor use and the risk of pneumonia in acute stroke: a retrospective analysis on susceptible patients. P LoS One 2017; 12(1): e0169300.Momosaki R., Yasunaga H., Matsui H., et al. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis 2016; 25(5): 1035–1040.Momosaki R., Yasunaga H., Matsui H., et al. Proton pump inhibitors versus histamine-2 receptor antagonists and risk of pneumonia in patients with acute stroke. J Stroke Cerebrovasc Dis 2016; 25(5): 1035–1040.Bateman B.T., Bykov K., Choudhry N. K., et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013; 347: f5416.Bateman B.T., Bykov K., Choudhry N. K., et al. Type of stress ulcer prophylaxis and risk of nosocomial pneumonia in cardiac surgical patients: cohort study. BMJ 2013; 347: f5416.Плотникова Е.Ю., Краснова М. В., Краснов К. А., Баранова Е. Н. Синдром избыточного бактериального роста, возникший в результате длительного приема ингибиторов протонной помпы. Медицинский альманах. 2015; 1(36): 53–55.Plotnikova E. Yu., Krasnova M. V., Krasnov K. A., Baranova E. N. The syndrome of excess bacterial overgrowth, which resulted from long intake of inhibitors of a proton pomp. Medical almanac. 2015; 1(36): 53–55.Leonard J, Marshall J.K, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102: 2047–2056.Leonard J, Marshall J.K, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007; 102: 2047–2056.Metz D. C. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol. 2008; 103: 2314–2316.Metz D. C. Clostridium difficile colitis: wash your hands before stopping the proton pump inhibitor. Am J Gastroenterol. 2008; 103: 2314–2316.Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium diffi cile. BMJ. 2008; 336: 109.Thachil J. Overprescribing PPIs: time for a hospital antacid policy on Clostridium diffi cile. BMJ. 2008; 336: 109.Food and Drug Administration (FDA) (2009) Updated Safety Information about a Drug Interaction between Clopidogrel Bisulfate and Omeprazole. Public Health Advisory. Available at: http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcare-Professionals/PublicHealth Advisories/ucm190825.htm (accessed 15 December 2011).Food and Drug Administration (FDA) (2009) Updated Safety Information about a Drug Interaction between Clopidogrel Bisulfate and Omeprazole. Public Health Advisory. Available at: http://www.fda.gov/Drugs/Drug-Safety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcare-Professionals/PublicHealth Advisories/ucm190825.htm (accessed 15 December 2011).Heidelbaugh J.J., Kim A. H., Chang R., Walker P. C. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul; 5(4): 219–232. doi: 10.1177/1756283X12437358.Heidelbaugh J.J., Kim A. H., Chang R., Walker P. C. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul; 5(4): 219–232. doi: 10.1177/1756283X12437358.Shiraki M., Yamasaki K., Ishiyama H., et al. Healing promoting effect of proamipide, a novel drug that increases gastric defense mechanisms, on acetic acid-induced gastric ulcers in the rat. Nippon Yakurigaku Zasshi. 1988; 92: 389–95.Shiraki M., Yamasaki K., Ishiyama H., et al. Healing promoting effect of proamipide, a novel drug that increases gastric defense mechanisms, on acetic acid-induced gastric ulcers in the rat. Nippon Yakurigaku Zasshi. 1988; 92: 389–95.Yamasaki K., Ishiyama H., Imaizumi T., et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jap J Pharmacol. 1989; 49: 441–8.Yamasaki K., Ishiyama H., Imaizumi T., et al. Effect of OPC-12759, a novel antiulcer agent, on chronic and acute experimental gastric ulcer, and gastric secretion in rats. Jap J Pharmacol. 1989; 49: 441–8.Kleine A., Kluge S., Peskar B. M. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993; 38: 1441–9.Kleine A., Kluge S., Peskar B. M. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993; 38: 1441–9.Ishiyama H., Yamasaki K., Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats. Jpn Pharmacol Ther. 1988; 16: 4103–9.Ishiyama H., Yamasaki K., Kanbe T. Effect of proamipide (OPC-12759) on gastric mucus secretion in rats. Jpn Pharmacol Ther. 1988; 16: 4103–9.Tarnawski A., Arakawa T., Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998; 43: 90S-8S.Tarnawski A., Arakawa T., Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998; 43: 90S-8S.Watanabe S., Wang X., Hirose M., et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci. 1998; 43: 107S-12S.Watanabe S., Wang X., Hirose M., et al. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci. 1998; 43: 107S-12S.Yoshikawa T., Naito Y., Nakamura S., et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneim Forsch / Drug Res. 1993; 43: 1327–30.Yoshikawa T., Naito Y., Nakamura S., et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indometacin in rats. Arzneim Forsch / Drug Res. 1993; 43: 1327–30.Suzuki M., Miura S., Mori M., et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut. 1994; 35: 1375–8.Suzuki M., Miura S., Mori M., et al. Rebamipide, a novel antiulcer agent, attenuates Helicobacter pylori induced gastric mucosal cell injury associated with neutrophil derived oxidants. Gut. 1994; 35: 1375–8.Aihara M., Azuma A., Takizawa H., et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci. 1998; 43: 174S-80S.Aihara M., Azuma A., Takizawa H., et al. Molecular analysis of suppression of interleukin-8 production by rebamipide in Helicobacter pylori-stimulated gastric cancer cell lines. Dig Dis Sci. 1998; 43: 174S-80S.Arakawa T., Kobayashi K., Yoshikawa T., et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998; 43: 5S-13S.Arakawa T., Kobayashi K., Yoshikawa T., et al. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998; 43: 5S-13S.Arakawa T., Kobayashi K. Quality of ulcer healing: a new concept to rank healed peptic ulcers. Gastroenterol Jpn. 1993; 28: 158–62.Arakawa T., Kobayashi K. Quality of ulcer healing: a new concept to rank healed peptic ulcers. Gastroenterol Jpn. 1993; 28: 158–62.Arakawa T., Nebiki H., Higuchi K., et al. Rebamipide, a gastroprotective drug, improves quality of healing and decreases recurrence of gastric ulcer without affecting Helicobacter pylori status [abstract]. Gastrointest Endosc. 1997; 45: AB87.Arakawa T., Nebiki H., Higuchi K., et al. Rebamipide, a gastroprotective drug, improves quality of healing and decreases recurrence of gastric ulcer without affecting Helicobacter pylori status [abstract]. Gastrointest Endosc. 1997; 45: AB87.Naito Y., Yoshikawa T., Iinuma S., Yagi N., Matsuyama K., Boku Y., et al. Rebamipide protects against indomethacininduced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43(9):83S-9S.Naito Y., Yoshikawa T., Iinuma S., Yagi N., Matsuyama K., Boku Y., et al. Rebamipide protects against indomethacininduced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43(9):83S-9S.Kim H.K., Kim J. I., Kim J. K., Han J. Y., Park S. H., Choi K. Y., et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci. 2007;52(8):1776–82. doi: 10.1007/s10620–006–9367-y.Kim H.K., Kim J. I., Kim J. K., Han J. Y., Park S. H., Choi K. Y., et al. Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers. Dig Dis Sci. 2007;52(8):1776–82. doi: 10.1007/s10620–006–9367-y.Terano A., Arakawa T., Sugiyama T., Suzuki H., Joh T., Yoshikawa T., et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690–3. doi: 10.1007/s00535–007–2076–2.Terano A., Arakawa T., Sugiyama T., Suzuki H., Joh T., Yoshikawa T., et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42(8):690–3. doi: 10.1007/s00535–007–2076–2.Kobayashi M., Takeuchi M., Hashimoto S., Mizuno K., Sato Y., Narisawa R., et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci. 2012;57(1):119–26. doi: 10.1007/s10620–011–1850–4.Kobayashi M., Takeuchi M., Hashimoto S., Mizuno K., Sato Y., Narisawa R., et al. Contributing factors to gastric ulcer healing after endoscopic submucosal dissection including the promoting effect of rebamipide. Dig Dis Sci. 2012;57(1):119–26. doi: 10.1007/s10620–011–1850–4.Kim J.H., Park S. H., Cho C. S., Lee S. T., Yoo W. H., Kim S. K., et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver. 2014;8(4):371–9. doi: 10.5009/gnl.2014.8.4.371.Kim J.H., Park S. H., Cho C. S., Lee S. T., Yoo W. H., Kim S. K., et al. Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory druginduced mucosal toxicity. Gut Liver. 2014;8(4):371–9. doi: 10.5009/gnl.2014.8.4.371.Kurokawa S., Katsuki S., Fujita T., Saitoh Y., Ohta H., Nishikawa K., et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014;49(2):239–44. doi: 10.1007/s00535–013–0805–2.Kurokawa S., Katsuki S., Fujita T., Saitoh Y., Ohta H., Nishikawa K., et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2014;49(2):239–44. doi: 10.1007/s00535–013–0805–2.Tozawa K., Oshima T., Okugawa T., Ogawa T., Ohda Y., Tomita T., et al. A randomized, double-blind, placebocontrolled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014;59(8):1885–90. doi: 10.1007/s10620–014–3108–4.Tozawa K., Oshima T., Okugawa T., Ogawa T., Ohda Y., Tomita T., et al. A randomized, double-blind, placebocontrolled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci. 2014;59(8):1885–90. doi: 10.1007/s10620–014–3108–4.Плотникова Е.Ю., Грачева Т. Ю. Эрозивно-язвенные поражения желудочно-кишечного тракта и простагландины: проблемный дуэт. Справочник поликлинического врача. 2016; 4: 32–37.Plotnikova E. Yu., Gracheva T. Yu. Erosive and ulcer damages of digestive tract and prostaglandins: problem duet. Reference book by the polyclinic doctor. 2016; 4: 32–37.Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573–86.Koyama N., Sasabe H., Miyamoto G. Involvement of cytochrome P450 in the metabolism of rebamipide by the human liver. Xenobiotica. 2002 Jul;32(7):573–86.

The authors declare that there are no conflicts of interest present.